PTEN deficiency is not only prevalent in prostate cancer, as current clinical trials are using p-AKT inhibitors (e.g., capivasertib) combined with abiraterone as a treatment for patients with metastatic prostate cancer. Here, AKT1 is linked to metastatic prostate carcinoma.